The global antibody fragments market size is expected to reach USD 11.71 billion by 2030, according to a new study by Polaris Market Research. The report “Antibody Fragments Market Share, Size, Trends, Industry Analysis Report, By Specificity (Monoclonal, Polyclonal); By Type (FAB, scFv); By Therapy; By Application; By Region; Segment Forecast, 2022 – 2030” gives a detailed insight into current market dynamics and provides an analysis of future market growth.
The rising cases of cancer across the globe contribute to the growth of the antibody fragment, and soon the, it will replace the full-length antibody. These are smaller in size and can be easily penetrated, thus being used in the treatment of diseases such as cancer, tumors, and COVID-19.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/antibody-fragments-market/request-for-sample
In addition, the growing geriatric population across developing economies such as India, Japan, Mexico, and China will positively impact the demand for the industry over the coming years. However, with the development of second and third-generation, the demand for first-generation will reduce. The COVID-19 pandemic positively impacted the demand for the industry, as these are used in the treatment of COVID-19. The industry will continue to expand with increased diseases. With the smaller size of the antibody, it is used to cure tumors as well.
Antibody Fragments Market Report Highlights
- The monoclonal antibodies dominated the industry owing to the antibodies’ homogeneous nature and production.
- The immunodeficiency segment dominates the market with the increasing prevalence of diseases globally. FAB segment is the first-generation antibody molecule and thus is used at a higher level.
- North America dominates the industry with the highest revenue share and is expected to grow with advanced infrastructure and technology over the forecast period.
- Major players operating in the industry include Pfizer Inc.; Ablynx; Novartis AG; Genentech, Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; Johnson & Johnson Private Limited; Eli Lilly, F. Hoffmann-La Roche AG; Amgen Inc.; The Takeda Pharmaceutical Company Limited; Sanofi S.A.; Biogen Inc.
Polaris Market Research has segmented the Antibody Fragments market report based on specificity, type, therapy, application, and region:
Antibody Fragments, Specificity Outlook (Revenue – USD Billion, 2018 – 2030)
- Monoclonal Antibodies
- Polyclonal Antibodies
Antibody Fragments, Type Outlook (Revenue – USD Billion, 2018 – 2030)
Antibody Fragments, Therapy Outlook (Revenue – USD Billion, 2018 – 2030)
- Monoclonal Antibodies
Antibody Fragments, Application Outlook (Revenue – USD Billion, 2018 – 2030)
Antibody Fragments, Regional Outlook (Revenue – USD Billion, 2018 – 2030)
- North America
- Asia Pacific
- South Korea
- Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa